PDS Biotechnology Corporation (PDSB)

Reiterating Outperform – Phase 2 Trial Meets Efficacy Endpoint


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
June 15, 2023
Report ID: 25916
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


PDS Biotechnology Corporation
PDS Biotechnology Corporation
Healthcare
Biotechnology
Ticker
PDSB
Current Price
$5.11 -1.92%
Market Cap
$157.7M
Price Target
Refer to Report
Volume
163.5K
52wk Range
$2.89 - $13.65
Related Research Reports
8/15/2023

2Q23 Achieves Important Milestones With More To Follow
2Q23 Achieves Important Milestones With More To Follow (PDSB)
7/18/2023

New PDS0301 Combination Data To Be Presented
New PDS0301 Combination Data To Be Presented (PDSB)
6/16/2023

Answering Questions About The VERSATILE-002 Data
Answering Questions About The VERSATILE-002 Data (PDSB)
6/15/2023

Reiterating Outperform – Phase 2 Trial Meets Efficacy Endpoint
Reiterating Outperform – Phase 2 Trial Meets Efficacy Endpoint (PDSB)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.